每经记者:许立波每经编辑:张海妮3月27日,创新药概念股走强,截至当日收盘,信达生物(HK01801)上涨17.41%,报45.850港元/股,市值超750亿港元。消息面上,信达生物于前一日(3月26日)披露2024年业绩公告。公司报告期内实现总收入94.22亿元,同比增长51.8%。公司称,强劲的业绩表现主要得益于达伯舒(信迪利单抗注射液)在内的主要产品保持收入的强劲增长以及新产品的快速放量。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.